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Oxcarbazepine (OXC) is indicated for treating partial-onset and generalized tonic–clonic seizures, in both adults and children
aged over 6 years, as monotherapy or adjuvant therapy. Trials data and extensive clinical experience demonstrate generally
good tolerability and antiepileptic efficacy similar to carbamazepine (CBZ), sodium valproate or phenytoin. Since the UK
launch of OXC in March 2000, UK collaborators have pooled experience to optimize prescribing recommendations for adults.
Many patients are successfully managed using the prescribing information recommended titration schedule. However, evolving
clinical experience suggests a slower introduction is preferable (e.g. 150 mg day one, then 300 mg daily, increased by 300 mg
weekly) both for monotherapy and adjuvant therapy. Overnight ‘switch’ from CBZ to OXC (using CBZ:OXC ratio of 1:1.5)
has been used for patients responsive to CBZ, but with dose-related side-effects. Owing to individual variations in CBZ enzyme
autoinduction, however, overnight switching is advised only for those on CBZ<800 mg daily; otherwise, slower switching
is recommended. OXC is not the first choice alternative for patients developing a CBZ rash owing to increased OXC rash
rate in CBZ sensitive subjects. Hyponatraemia may be more common (albeit often asymptomatic) than trials data suggest,
especially in the elderly. Serum sodium monitoring is unnecessary, however, unless relevant risk factors or pointers exist. Severe
haematological dyscrasias have not been reported with OXC. The enzyme inducing interaction of OXC with ethinyloestradiol
and levonorgestrel necessitates additional precautions for women using hormonal contraception.
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INTRODUCTION
The challenge of epilepsy management
An estimated 50 million people worldwide suffer from
epilepsy. With an ageing population, more people sur-
viving serious head trauma, and stroke, the number
of people experiencing seizures is increasing. Par-
tial seizures are the most common type, occurring in
about 60% of all patients with epilepsy. Up to 30%
of all patients with epilepsy will not achieve adequate
seizure control and their lives are blighted by adverse
events as a result of drug therapy as well as seizures.
The impetus to develop new drugs to treat epilepsy is
driven by the need for new AEDs that are at least as
effective as existing therapies, but are better tolerated.
Oxcarbazepine
Oxcarbazepine (Trileptal) was launched in the UK
in March 2000. At launch, oxcarbazepine was indi-
cated for use as monotherapy and adjunctive therapy
for patients with partial seizures with or without sec-
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ondary generalized tonic–clonic seizures. Clinical ex-
perience worldwide is already extensive and spans
more than 250 000 patient years. This compares with
the consideration that 100 000 patient years of expe-
rience is sufficient to determine idiosyncratic adverse
events1.
The clinical trials programme for oxcarbazepine
was extensive. It has been evaluated against placebo
as well as in head-to-head comparative trials with
three AEDs traditionally considered as first-choice
agents (carbamazepine [CBZ], valproate and pheny-
toin) where it demonstrated comparable efficacy2–4. In
monotherapy comparative trials seizure freedom was
achieved in 52%, 57% and 59% of patients receiv-
ing oxcarbazepine vs. CBZ, valproate or phenytoin2–4.
Oxcarbazepine was significantly better tolerated than
CBZ (P = 0.04) and phenytoin (P = 0.02), accord-
ing to the discontinuation rates due to adverse events.
Oxcarbazepine has also been shown to be effective
in adjunctive trials, one in adults and one in children,
where it demonstrated dose-dependent efficacy when
added to drug regimens of at least two AEDs5, 6. Ox-
carbazepine demonstrated a dose-dependent effect on
seizure control with a reduction in seizure frequency
from baseline at 600, 1200 and 2400 mg per day of
26%, 40% and 50%, respectively5. In add-on ther-
apy, seizure freedom could be achieved in a dose-
dependent manner so that at 600 mg per day 3% of
patients were seizure free, rising to 22% of patients be-
coming seizure free at the top dose of oxcarbazepine
of 2400 mg per day5.
Dosing
Currently, when used as monotherapy it is recom-
mended that oxcarbazepine should be initiated at a
dose of 600 mg per day administered twice daily as
a divided dose. If clinically required, the dose of ox-
carbazepine can be increased at weekly intervals by
600 mg per day until seizure control is achieved up
to a maximum dose of 2400 mg per day. Generally, a
therapeutic response is observed at 1200 mg per day in
previously treatment naive patients (900–1200 mg per
day is a usual target dose) and at 2400 mg per day
for patients with refractory seizures where previous
monotherapy has failed7. If rapid seizure control is
required, the dose of oxcarbazepine can be increased
rapidly to 2400 mg per day over 48 hours in a con-
trolled hospital setting8.
Similarly, when oxcarbazepine is prescribed as ad-
junctive therapy in adults it is recommended that treat-
ment is initiated at 600 mg per day and titrated at
weekly intervals by 600 mg per day. In a clinical
trial of oxcarbazepine as add-on therapy it was shown
to have a dose-dependent effect on seizure control
with up to 22% of patients achieving seizure free-
dom5.
CURRENT CLINICAL EXPERIENCE
Current clinical experience has shown that if oxcar-
bazepine therapy is initiated and titrated as per the pre-
scribing information (PI)9, some patients have an ex-
cellent response whilst others have a less positive out-
come. For some patients, initiation of oxcarbazepine
at 600 mg per day and titration on a weekly basis of
600 mg per day is well tolerated and effective. But for
other patients, this dosing and titration schedule has
proved unsuccessful with instances of poor tolerabil-
ity for both monotherapy and adjunctive therapy.
Evolving clinical experience is demonstrating that a
‘go low, go slow’ approach would be more appropriate
for some patients. The dosing schedule recommended
in the PI has been derived from clinical trials experi-
ence where strict exclusion and inclusion criteria oper-
ate, for this reason actual clinical experience can differ
markedly for some patients, whilst for others the rec-
ommended dosing schedule from the PI remains more
appropriate.
A meeting of the UK oxcarbazepine advisory panel
of epileptologists was convened with a view to es-
tablishing best clinical practice for adults. From this
a consensus opinion could be disseminated to all
specialists to improve clinical practice with oxcar-
bazepine and ultimately patient care. The recommen-
dations for the use of oxcarbazepine in children remain




• It was recommended that oxcarbazepine could be
used effectively as first-line monotherapy in treat-
ment naive patients.
• To improve patient outcome it was recommended
that for most patients oxcarbazepine monotherapy
could be initiated at 300 mg per day and titrated at
weekly intervals by 300 mg per day.
• It was recommended that treatment with oxcar-
bazepine be initiated in the following way: a first
dose of oxcarbazepine 150 mg be administered to
patients at bedtime on day 1 and then treatment
continued at 300 mg per day from day 2 (adminis-
tered as a divided dose).
• Using this schedule, the incidence of rash is likely
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to be reduced and tolerability improved. Therapeu-
tic doses (900–1200 mg per day) are still reached
quickly (within 2–3 weeks).
• Rapid initiation-titration with oxcarbazepine can
be undertaken if clinically needed, but this should
be considered only for very close supervision
within a ward setting.
Adjunctive therapy
• It is recommended that when oxcarbazepine is
added to a drug regimen it should ideally eventu-
ally substitute for one of the existing drugs.
• As in monotherapy, it was recommended that a
‘go low, go slow’ approach be adopted, and that
the overall drug burden for an individual patient
be considered. When deciding to initiate oxcar-
bazepine as add-on therapy in patients already re-
ceiving AEDs, clinicians need to consider care-
fully the overall drug burden for the patient, as
tolerability in these patient groups is mainly de-
pendent on the concomitant drug load. Hence it
may be prudent to reduce the dose of concomitant
AED therapy prior to and during initiation of ox-
carbazepine. If oxcarbazepine is replacing one or
more of the AED therapies (e.g. CBZ), the panel
felt that clinicians should be aware of potential in-
creases in the total drug load—due to the lack of
autoinduction of oxcarbazepine.
• It was recommended that oxcarbazepine should
be considered as adjunctive therapy firstly for
patients not receiving carbamazepine and secondly
for patients receiving carbamazepine<800 mg per
day.
• For patients receiving carbamazepine as part of
their drug regimen the dose of oxcarbazepine
should be introduced cautiously and the dose of
carbamazepine reduced to below the maximum
tolerated dose of CBZ (i.e. <800 mg per day), in
order to circumvent tolerability issues.
• For patients on high doses of concomitant AEDs
it was recommended that oxcarbazepine should be
added into the regimen more slowly than recom-
mended in the PI, and that the initiation dose of ox-
carbazepine be considered in light of the patient’s
overall drug burden. It has been suggested that
for patients receiving 2–3 AEDs initiation may
need to be very slow with an initiation dose of
150 mg per day, whilst those receiving 1–2 AEDs
oxcarbazepine might be initiated faster at a dose of
300 mg per day.
Switch therapy
• Where possible substitution therapy is preferable
to add-on therapy to circumvent increasing a
patient’s overall drug burden.
• It is recommended that immediate (‘overnight’)
switch should be considered only for patients re-
ceiving CBZ monotherapy (ideally, <800 mg per
day), but who are intolerant of its side effects or
are experiencing inadequate seizure control. For
patients in other situations (particularly those re-
ceiving AED polytherapy) a gradual switch over
2–3 weeks is more appropriate: gradual conver-
sion from CBZ to oxcarbazepine may be achieved
by initiating oxcarbazepine as 150 mg b.i.d, and
then titrating upwards by 150 mg every 2 days.
This switch method is still rapid and ensures that
patients achieve seizure control quickly. The CBZ
should be reduced by 25% prior to the titration
of oxcarbazepine, to avoid problems of increased
drug load (due to lack of autoinduction by ox-
carbazepine), which could potentially lead to in-
creased tolerability issues.
• Rapid switching from CBZ to oxcarbazepine when
the dose of CBZ is below 800 mg per day is
thought not to be problematic. However, when a
switch is undertaken in patients receiving more
than 800 mg per day, clinical experience has
shown that, in some cases, patients may experience
increased side effects. This is thought to be due
to the variable degree of CBZ autoinduction from
patient to patient, which could result in the same
plasma concentration of CBZ occurring in patients
receiving 1 or 2 g per day, depending on the extent
of autoinduction. Using equivalent doses of oxcar-
bazepine in this situation is clearly inappropriate.
• Commonly in the UK slow release carbamazepine
is used (Tegretol Retard). When switching from
newer formulations of CBZ (i.e. slow release) to
oxcarbazepine, US experience has shown that a
1 : 1 or 1 : 1.2 switch is preferable due to dif-
ferences in pharmacokinetics between slow release
formulations of CBZ and conventional formula-
tions of CBZ (compared with Danish experience of
conventional CBZ: oxcarbazepine ratio 1 : 1.5)9.
• Importantly, if a patient has experienced a rash
with carbamazepine before switch to oxcar-
bazepine, then oxcarbazepine therapy should ide-
ally be initiated using the lower, slower initiation-
titration schedule recommended here to prevent
cross-sensitivity. This is, of course, dependent on
individual patient circumstances and the balance
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of seizure control against side effects. Oxcar-
bazepine would not be the first choice therapy for
switch medication for patients experiencing a pre-
vious rash with carbamazepine.
• Clinicians need to be aware that oxcarbazepine is
not an autoinducing drug. Thus, it is possible that
switching from an autoinducing drug (e.g. CBZ) in
AED polytherapy to oxcarbazepine, can increase
the plasma concentrations of the drugs remaining
in the regimen—this may result in increased side
effects, care should therefore be exercised in these
patients to ensure a positive outcome.
Safety
• It is noted that the incidence of hyponatraemia
appears to be dose dependent and that a slower,
lower titration-initiation schedule such as that rec-
ommended here may help to prevent it.
• Clinical experience suggests that hyponatraemia
(<125 mmol l−1 plasma sodium levels) may be
commoner in clinical practice than seen in the
clinical trials programme. However, most of these
patients are asymptomatic, and hyponatraemia, if
it occurs, tends to develop within the first 3 months
of treatment, consistent with the clinical trials data.
• It is recommended that hyponatraemia be managed
through water restriction, dose reduction and, if
required, discontinuation. The panel recommend
that clinicians question their patients about their
fluid intake.
• Routine monitoring for lowered plasma sodium is
not necessary, except for patients receiving con-
comitant sodium depleting drugs (e.g. diuretics) or
those with sodium-depleting disease, and may be
advisable in patients exhibiting related symptoms
(blurred vision, oedema, headache, confusion and
worsening seizures).
• However, it is recommended that clinicians use
their discretion and monitor patients who they
deem to be at risk. Hyponatraemia is more com-
mon in elderly patients and these patients should
be considered to be at a higher risk.
• The overall tolerability of oxcarbazepine is good.
Oxcarbazepine is not associated with severe blood
dyscrasias, agranulocytosis or aplastic anaemia.
• It was recommended that all women of child-
bearing age receiving oxcarbazepine (which is en-
zyme inducing with oral contraceptives) should
be carefully counselled about the impact of ox-
carbazepine on the contraceptive pill, prescribed a
pill containing 50 µg of oestrogen and use addi-
tional barrier methods of contraception until hor-
monal cover is established (e.g. lack of break-
through bleeding).
• However, some authorities recommend that all
women taking an enzyme-inducing AED and a
combined oral contraceptive, even if they are
receiving a higher oestrogen dose and have
good cycle control, should also use a barrier
method of contraception or a spermicide as well.
Progesterone-only oral contraceptives (mini-pill)
taken with an enzyme-inducing AED cannot be
relied upon to have their usual contraceptive effi-
cacy10.
CONCLUSIONS
Since launch, it is clear that oxcarbazepine has
proved to be an effective and well tolerated treat-
ment of epilepsy. Oxcarbazepine does have benefits
for patients, it is an effective and well tolerated drug
with no evidence of haematological toxicity. These
recommendations from the panel will serve to improve
clinical practice and benefit patients.
For some patients, oxcarbazepine can be used suc-
cessfully as recommended in the PI. For others, how-
ever, oxcarbazepine therapy would be most beneficial
if initiated at a lower dose over a slower timeframe
than originally recommended. For patients already re-
ceiving other AEDs, oxcarbazepine is most suitable as
an alternative therapy, but can be used successfully as
add-on therapy after consideration of the impact of the
lack of autoinduction and overall drug burden for the
patient.
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